# Zimberelimab

Source: https://onco.cc/drugs/zimberelimab/  
OnCo record `zimberelimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab.

## Summary

Guangzhou Gloria Biosciences' zimberelimab (GLS-010) received NMPA approval in 2021 for relapsed or refractory classical Hodgkin lymphoma after at least two lines of therapy, with a later cervical cancer indication. Outside China, Arcus Biosciences licensed it as AB122 and uses it as the PD-1 backbone with domvanalimab in the STAR-121 and STAR-221 phase 3 trials in lung and gastro-oesophageal cancer. A phase 3 trial in cervical cancer is registered in China.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: AB122
- Tags: pipeline; ctgov-ingest
- Code: GLS-010
- Modality: Anti-PD-1 monoclonal antibody, intravenous
- Mechanism: Blocks PD-1 on T cells so tumour cells cannot switch them off through PD-L1.
- Approvals: CN 2021: Relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy

## Sources

- ClinicalTrials.gov: trials of Zimberelimab: https://clinicaltrials.gov/search?intr=GLS-010

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- trials: [A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies](https://onco.cc/trials/nct05329766/), [A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic](https://onco.cc/trials/nct05798819/), [A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o](https://onco.cc/trials/nct06155396/), [Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07710885/), [Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors](https://onco.cc/trials/nct05909436/), [Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer](https://onco.cc/trials/nct04736173/), [Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst](https://onco.cc/trials/nct06727565/), [Study of Novel Treatment Combinations in Patients With Lung Cancer](https://onco.cc/trials/nct05633667/), [Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread](https://onco.cc/trials/nct03547973/), [Study With Various Immunotherapy Treatments in Participants With Lung Cancer](https://onco.cc/trials/nct05676931/)

---
JSON: https://onco.cc/api/v1/entities/zimberelimab.json